USAResearch and clinical trials
Carbetocin nasal spray did not reduce overeating in Prader-Willi syndrome in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In 175 people with Prader-Willi syndrome, carbetocin given as a nasal spray was compared with placebo. Treatment lasted 12 weeks. Excessive hunger decreased to a similar degree in both groups. The drug was not found to be better than placebo. The most common side effects were headache and fever.
What does it mean for patients and families?
This drug showed no benefit in this study. Diet and close supervision remain the basis for managing excessive hunger.
Source
Scientific paper: Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study. Clinical Therapeutics, 2026. DOI: 10.1016/j.clinthera.2026.06.019 · PubMed 42486751
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Prader-Willi syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.